Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TVNQB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ADC Trast-11
|
|||||
| Synonyms |
ADCTrast-11; ADC-Trast-11
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.9
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
PBD dimer 3
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Bis-BCN-modified Val-Cit-PABC linker 10
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.02 nM | High HER2 expression (HER2+++) | ||
| Method Description |
In vitro cytotoxicity of ADCs against a panel of four human breast cancer cell lines.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 100 nM | Negative HER2 expression (HER2-) | ||
| Method Description |
In vitro cytotoxicity of ADCs against a panel of four human breast cancer cell lines.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.